{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wan L"],"funding":["National Natural Science Foundation of China","Chongqing Natural Science Foundation"],"pagination":["102923"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12933863"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37"],"pubmed_abstract":["Oncolytic peptides offer a novel anticancer paradigm by inducing membrane lysis-mediated cancer cell death and subsequent anticancer immunity to overcome tumor heterogeneity and treatment resistance. Despite its promising profiles, the clinical application of oncolytic peptides (such as LTX-315) is hampered by ticklish reasons like rapid plasma clearance, suboptimal biodistribution, and potential toxicity toward normal tissues. Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy. The LCMBs enabled the targeted delivery and stimuli-responsive release of LTX-315 in the tumor site under low-intensity focused ultrasound (US). The high accumulation of"],"journal":["Materials today. Bio"],"pubmed_title":["Ultrasound-propelled oncolytic biomimetic microbubbles as <i>in situ</i> vaccines reprogram tumor immunosuppressive microenvironment."],"pmcid":["PMC12933863"],"funding_grant_id":["CSTB2025NSCQ-GPX1150","82572256","82404524","CSTB2024NSCQ-KJFZMSX0005"],"pubmed_authors":["Fu R","Jiao M","Yu L","Wu N","Chen J","Wan L","Tang C","Li P","Li R","Li X","Huang Z","Hu J","Tang R","Xia C","Liang P"],"additional_accession":[]},"is_claimable":false,"name":"Ultrasound-propelled oncolytic biomimetic microbubbles as <i>in situ</i> vaccines reprogram tumor immunosuppressive microenvironment.","description":"Oncolytic peptides offer a novel anticancer paradigm by inducing membrane lysis-mediated cancer cell death and subsequent anticancer immunity to overcome tumor heterogeneity and treatment resistance. Despite its promising profiles, the clinical application of oncolytic peptides (such as LTX-315) is hampered by ticklish reasons like rapid plasma clearance, suboptimal biodistribution, and potential toxicity toward normal tissues. Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy. The LCMBs enabled the targeted delivery and stimuli-responsive release of LTX-315 in the tumor site under low-intensity focused ultrasound (US). The high accumulation of","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Apr","modification":"2026-07-16T22:11:54.047Z","creation":"2026-07-14T03:04:09.414Z"},"accession":"S-EPMC12933863","cross_references":{"pubmed":["41756527"],"doi":["10.1016/j.mtbio.2026.102923"]}}